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INTRODUCTION
Waldenstrom’s macroglobulinemia (WM) is the result of
a clonal proliferation of lymphocytes that produce mono-
clonal immunoglobulin M (IgM). This disease was original-
ly described in 1944 by Jan Waldenstrom. It is now consid-
ered to correspond to lymphoplasmacytoid lymphoma as
defined by the World Health Organization classification sys-
tem (1, 2). Its clinical features include hyperviscosity, cytope-
nia, bleeding, lymphadenopathy, and/or splenomegaly. Many
central nervous system (CNS) complications have been des-
cribed in WM patients; the majority have been associated
with blood hyperviscosity caused by IgM. The hyperviscosi-
ty syndrome is characterized by headache, tinnitus, vertigo,
blurred vision, and chronic bleeding from the nose and gums
(3). However, CNS infiltration by plasmacytoid lymphocytes
(Bing-Neel syndrome) has only rarely been reported (4).
CASE REPORT
A 51-yr-old woman was diagnosed with WM three years
prior to this presentation. She received six courses of chloram-
bucil (0.3 mg/kg per day on day one to four orally) and pred-
nisone (45 mg/m2 per day on day one to four). However, the
disease progressed. Next, she received fludarabine chemother-
apy (25 mg/m2 per day on day one to five intravenously) with
a limited response. High-dose cyclophosphamide and gran-
ulocyte colony-stimulating factor were administered to induce
peripheral blood progenitor cell (PBPCs) mobilization for
autologous stem-cell transplantation; however, the number
of PBPCs collected was not sufficient. We then decided on
a conservative treatment approach, because the patient did
not have specific symptoms and the serum IgM level was
stable (3,000-3,500 mg/dL). She was admitted to the hospi-
tal because of persistent headache and increased IgM levels.
Physical examination was unremarkable. The laboratory val-
ues on admission were as follows: white cell count 8,050/ L
with normal differential counts, hemoglobin 9.6 g/dL, platelets
296,000/ L, erythrocyte sedimentation rate 144 mm/hr,
total protein 9.44 g/dL, albumin 2.85 g/dL, IgG 3144.4 mg/
dL, IgA 25.4 mg/dL, IgM 4904.6 mg/dL, and serum  2-
microglobulin 3.81 mg/L. A brain computed tomography
scan revealed multifocal extra-axial tumorous lesions along
the dura matter. A brain magetic resonance imaging showed
an extra-axial soft tissue tumor along the left cavernous sinus
and tentorium, right frontal convexity and tentorium and
falx; the brain parenchyma appeared to be unremarkable (Fig.
1A). Cerebrospinal fluid analysis showed the following: white
cell count 43/ L with neutrophils 1%, lymphocytes 52%
and monocytes 47%, total protein 1.81 g/dL, glucose 104
mg/dL, IgM 64.5 mg/dL and a few plasmacytoid lympho-
cytes on cytology. Stereotactic biopsy of dural tissue at the
falx showed a diffuse infiltration with atypical cells, which
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Therapeutic Experience of Bing-Neel Syndrome Associated with
Waldenstrom’ s Macroglobulinemia
Waldenstrom’s macroglobulinemia is an uncommon low-grade B-cell lymphopro-
liferative disorder in which monoclonal immunoglobulin M is produced. Neurologi-
cal symptoms due to hyperviscosity are frequent manifestations of Waldenstrom’s
macroglobulinemia. However, central nervous system infiltration by plasmacytoid
lymphocytes (Bing-Neel syndrome) has only rarely been reported. We report a case
of a 51-yr-old woman suffering from Waldenstrom’s macroglobulinemia who com-
plained of persistant headache. Brain magnetic resonance imaging revealed an
extra-axial soft tissue mass along the left cavernous sinus, left tentorium, right ten-
torium, and falx cerebri. A stereotactic biopsy of dural tissue from the falx was per-
formed and showed plasmacytoid lymphocyte infiltration. The patient became symp-
tom-free with irradiation of the whole brain followed by chemotherapy with fludara-
bine.
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were identified immunophenotypically as plasmacytoid lym-
phocyte with expression of LCA (+), CD3 (-), CD20 (+),
and VS38a (+) (Fig. 2). The patient was confirmed to have
CNS infiltration by atypical plasmacytoid lymphocyte infil-
tration (Bing-Neel syndrome). The paitent received a total
dose of 1,980 cGy with irradiation therapy of the whole brain
that was administered in 11 fractions, and then her headache
subsided, but the IgM level was elevated persistently to
3,379.8 mg/dL. Following radiation therapy, fludarabine
chemotherapy was performed (25 mg/m2 per day on 1 to 5
intravenously, two courses). Further treatment was not possi-
ble because of persistant bone marrow suppression. A follow-
up brain MRI after six months revealed a marked decrease
in the size of the mass in the tentorium and falx (Fig. 1B).
The patient had no evidence of CNS recurrence during the
follow-up period of one year. However, the IgM level has
been increasing slowly, so further chemotherapy, including
rituximab may be considered.
DISCUSSION
In 1936 Bing and Neel reported the association of hyper-
globulinemia, CNS symptoms (paresthesias, headache, and
paralysis), and brain infiltration composed of plasma cells
and lymphocytes in two patients (5). In 1944, Waldenstrom
described the syndrome that bears their name (Bing-Neel
syndrome) (6). The Bing-Neel syndrome, originally placed
in a ‘‘toxic-infectious’’ category, appears to be the result of
involvement of the CNS by diffuse neoplasm infiltration.
Neurological complications occur in about 25% of patients
with WM. Although they are most often peripheral, they
can involve the CNS. In WM, the CNS may be involved by
a variety of mechanisms, including hyperviscosity and direct
infiltration by neoplastic cells (7, 8). Patients with Bing-Neel
syndrome have sometimes presented with a mass containing
neoplastic cells, but the masses have been intraparenchymal
rather than meningeal (8, 9). This syndrome can be subdi-
vided into diffuse and tumoral forms. In the diffuse infiltra-
tive form such as this case, malignant cells are localized main-
ly in leptomeningeal spaces, periventricular white-matter,
pons, and medulla (7, 10-12). Radiological findings in this
syndrome have been reported, but a typical pattern has not
emerged (13-15). An imaging technique would be the pre-
ferable diagnostic test, although histological confirmation is
necessary to establish the definitive diagnosis.
Intraventricular chemotherapy for Bing-Neel syndrome
was reported to be effective in 1984 (15). However, a review
of the literature reveals that the outcome for most patients
who underwent chemotherapy was poor, and the patients
died within several months (10, 13, 14). Therefore, patients
with Bing-Neel syndrome may benefit from cranial radia-
tion therapy prior to chemotherapy (9, 12, 16). Recently, a
great deal of interest has been noted by treatments with pu-
rine nucleoside analogs (fludarabine, cladribine, and pento-
statin) because of their remarkable activity in lymphoprolif-
erative disorders. It has been reported that a patient with
Bing-Neel syndrome (in its diffuse form) was successfully
treated with cladribine administration (17), or radiation ther-
apy and combination of cladribine, cyclophosphamide, and
prednisone (18). In the present case, headache subsided after
radiation therapy, but the IgM level increased persistently.
Therefore, following radiation therapy we used fludarabine
for two courses. Further treatment was not possible because
of persistant bone marrow suppression. A follow-up brain
MRI after six months revealed a marked decrease in the size
of the mass in the tentorium and falx; the patient had no
evidence of CNS recurrence during the follow-up period of
one year, but the IgM level has been increasing slowly. We
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Fig. 1. (A) Contrast enhanced axial and coronal T1-weighted
images show a well-enhanced mass along the left tentorium and
cavernous sinus (arrows). This mass also extends into the con-
tralateral tentorium and falx (arrowheads). (B) Marked decrease in
the size of the mass in the tentorium and falx after radiation thera-
py and  fludarabine treatment.
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Fig. 2. Stereostactic brain biopsy showing diffuse infiltration of aty-
pical plasmacytoid lymphocytes into the dural fibrous tissue (A)
Hematoxylin & eosin (original magnification ×200); (B) Positive
immunohistochemical staining for CD20 (original magnification
×40).CNS Involvement in Waldenstrom’s Macroglobulinemia 1081
think that the major effect of deceased mass size was due to
the radiation therapy in the present case.
Several retrospective and prospective studies have indicat-
ed that rituximab may induce an objective response in app-
roximately 30-40% of previous treated patients with WM
(19). However, the effect of rituximab treatment on the cere-
brospinal fluid B-cell compartment is limited in compari-
son with the effect on the B cells in the periphery (20), and
it has not been tried in Bing-Neel syndrome as yet. There-
fore, the effect of rituximab on CNS involovement of WM
need to be validated by of future studies. 
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